By issuing warrants on shares, the German-American company Pieris Pharmaceuticals (spin-off of the Technical University of Munich) has been able to raise a good 32 million US dollars from private investment companies.
The warrants are intended in particular to provide better financial support for Poieris' clinical programs and to form a basis for actually being able to use the independent development options from the partnership with AstraZeneca. Participants in this "private placement" were BVF Partners L.P., EcoR1 Capital, Aquilo Capital Management, Surveyor Capital und Samsara BioCapital.
More information:
https://www.pieris.com/news-and-events/press-releases